Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer
- Focus Adverse reactions
- 29 May 2019 Planned number of patients changed from 17 to 33.
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.